



New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents

Laurent R. Chiarelli, Matteo Mori, Giangiacomo Beretta, Arianna Gelain, Elena Pini, Josè Camilla Sammartino, Giovanni Stelitano, Daniela Barlocco, Luca Costantino, Margherita Lapillo, Giulio Poli, Isabella Caligiuri, Flavio Rizzolio, Marco Bellinzoni, Tiziano Tuccinardi, Stefania Villa & Fiorella Meneghetti

To cite this article: Laurent R. Chiarelli, Matteo Mori, Giangiacomo Beretta, Arianna Gelain, Elena Pini, Josè Camilla Sammartino, Giovanni Stelitano, Daniela Barlocco, Luca Costantino, Margherita Lapillo, Giulio Poli, Isabella Caligiuri, Flavio Rizzolio, Marco Bellinzoni, Tiziano Tuccinardi, Stefania Villa & Fiorella Meneghetti (2019) New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents, *Journal of Enzyme Inhibition and Medicinal Chemistry*, 34:1, 823-828, DOI: [10.1080/14756366.2019.1589462](https://doi.org/10.1080/14756366.2019.1589462)

To link to this article: <https://doi.org/10.1080/14756366.2019.1589462>



© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



[View supplementary material](#)



Published online: 20 Mar 2019.



[Submit your article to this journal](#)




















Article views: 200



[View Crossmark data](#)

New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents


Laurent R. Chiarelli^{a*} , Matteo Mori^{b*} , Giangiacomo Beretta^c , Arianna Gelain^b , Elena Pini^b ,
Josè Camilla Sammartino^a , Giovanni Stelitano^a , Daniela Barlocco^b , Luca Costantino^d ,
Margherita Lapillo^e , Giulio Poli^e , Isabella Caligiuri^f , Flavio Rizzolio^{f,g} , Marco Bellinzoni^h ,
Tiziano Tuccinardi^e , Stefania Villa^b  and Fiorella Meneghetti^b 

^aDepartment of Biology and Biotechnology “L. Spallanzani”, University of Pavia, Pavia, Italy; ^bDepartment of Pharmaceutical Sciences, University of Milano, Milano, Italy; ^cDepartment of Environmental Science and Policy, University of Milano, Milano, Italy; ^dDepartment of Life Sciences, University of Modena e Reggio Emilia, Modena, Italy; ^eDepartment of Pharmacy, University of Pisa, Pisa, Italy; ^fPathology Unit, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, Aviano, Italy; ^gDepartment of Molecular Science and Nanosystems, Ca’ Foscari University of Venezia, Venezia-Mestre, Italy; ^hInstitut Pasteur, Paris, France

ABSTRACT

Starting from the analysis of the hypothetical binding mode of our previous furan-based hit (**I**), we successfully achieved our objective to replace the nitro moiety, leading to the disclosure of a new lead exhibiting a strong activity against MbtI. Our best candidate **1h** displayed a K_i of 8.8 μM and its antimycobacterial activity ($\text{MIC}^{99} = 250 \mu\text{M}$) is conceivably related to mycobactin biosynthesis inhibition. These results support the hypothesis that 5-phenylfuran-2-carboxylic derivatives are a promising class of MbtI inhibitors.

GRAPHICAL ABSTRACT



ARTICLE HISTORY

Received 11 February 2019
Revised 22 February 2019
Accepted 25 February 2019



KEYWORDS

Tuberculosis; siderophores; mycobactins; drug design; antimycobacterial agent; molecular modelling


Introduction

Tuberculosis (TB) is an infectious disease caused by an obligate aerobic bacterium, known as *Mycobacterium tuberculosis* (Mtb). When the bacilli are inhaled, they reach the alveolar spaces of the lungs and are mainly ingested by macrophages. As a consequence, TB primarily affects the lungs, but at later stages it can also spread to other vital organs. Despite significant improvements with respect to diagnosis, treatment, and preventive measures have been successfully implemented in many healthcare

systems around the world, this disease still remains the world's biggest threat to human health causing 54 million deaths between 2000 and 2017¹. Standard therapeutic regimens have remained substantially unchanged over the past 60 years with outdated drugs and very long therapies that are still used for the treatment of new and relapse cases. In addition to the length of the cure, other hurdles related to the management of TB infections include interactions with drugs used in comorbid conditions, especially HIV, and severe side effects. All these issues contribute


CONTACT Stefania Villa  stefania.villa@unimi.it  Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via L. Mangiagalli 25, Milano 20133, Italy

*These authors contributed equally to this work.

 Supplemental data for this article can be accessed [here](#).

© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1. *In vitro* activity of compounds **1a–p**.


1a–i R ₁ =CF ₃				1j–p R ₁ =NO ₂			
Code	R ₂	Residual activity at 100 μM (%)	Mbtl IC ₅₀ (μM)*	Code	R ₂	Residual activity at 100 μM (%)	Mbtl IC ₅₀ (μM)*
1a	Cl	6.1 ± 2.5	28.5 ± 2.6	1 ^{**}	Cl	11.3 ± 4.2	17.9 ± 3.2
1b	F	6.1 ± 1.1	27.6 ± 7.3	1j	F	32.1 ± 2.4	–
1c	Br	38.0 ± 3.7	–	1k	Br	26.4 ± 4.8	–
1d	OH	16.8 ± 2.7	35.9 ± 10.3	1l	OH	13.9 ± 4.0	29.8 ± 4.2
1e	CH ₃	19.3 ± 2.2	31.5 ± 9.6	1m	CH ₃	13.2 ± 5.8	28.5 ± 1.5
1f	NH ₂	13.1 ± 2.4	34.6 ± 10.9	1n	NH ₂	13.5 ± 3.8	24.2 ± 5.4
1g	CN	5.7 ± 1.5	18.5 ± 3.2	1o	CN	5.0 ± 1.9	24.4 ± 5.9
1h	CF ₃	3.9 ± 1.7	13.1 ± 2.0	1p	CF ₃	25.1 ± 3.7	41.8 ± 5.3
1i	<i>m</i> -CF ₃	64.3 ± 4.5	–	–	–	–	–

*Only for compounds with residual activity ≤25%; **new fluorimetric assay value determined for the sake of comparison.

to determine a poor patient compliance that, together with the improper use of TB antibiotics, has led to the insurgence of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) bacterial strains^{2–4}. As confirmed by the latest WHO report, drug resistance is becoming a real emergency; therefore, there is a growing interest in the development of novel anti-TB compounds^{5–8}. A few of them reached clinical trials and two drugs, delamanid and bedaquiline, have been recently approved; however, more information on their effectiveness, safety, and tolerability are still required because severe side effects have been reported^{9,10}. In this scenario, the research of many more TB drug candidates to sustain an effective and productive drug pipeline is pivotal. Targeting Mtb iron uptake systems is now a validated strategy for the development of antimycobacterial compounds, because iron is essential for Mtb survival in the host and its acquisition is strongly correlated with virulence¹¹. Among the four different iron acquisition pathways used by Mtb, the most thoroughly characterised one is based on the production of two types of siderophores: carboxymycobactins, which acquire iron extracellularly and transport it into the cytoplasm of the bacteria, and mycobactins, which facilitate the transport of iron through the cell wall into the cytoplasm. Notably, targeting this biosynthetic process is an attractive strategy, because its impairment lowers the pathogen virulence and survival without causing toxicity issues. Indeed, as this pathway is absent in humans, the risk of off-target effects is minimal; moreover, being an unexplored biological process for the development of drugs, there is no known resistance mechanism. The first step of the biosynthesis of these siderophores is catalysed by the Mg²⁺-dependent enzyme salicylate synthase (Mbtl), a validated pharmacological target^{12–15}, whose crystal structure has been recently solved¹⁶.

In this context, the aim of our project is the identification of new Mbtl inhibitors as potential antitubercular agents. Our previous computational studies generated a pharmacophore model, that allowed the identification of the interesting hit compound **1** (Table 1). Then, a structure-activity relationship study on monosubstituted derivatives underlined the importance of the nitro moiety for potency¹⁴. However, the nitro group is considered a structural alert for the development of a potential drug, since drugs containing nitro groups have been extensively associated with mutagenicity and genotoxicity¹⁷. On these bases, in the present work, we designed additional analogs (compounds **1a–p**, Table 1) exploring other hitherto unconsidered pharmacophoric features and evaluating the possibility of replacing the nitro group.

Materials and methods

Chemistry

Compounds **1a,b,d–i,l–n,p** were synthesised by a Suzuki-Miyaura reaction¹⁸, followed by a base-catalysed hydrolysis of the ester function¹⁹. Compounds **1c,j,k,o** were synthesised by a Sandmeyer reaction²⁰, starting from 2-furan carboxylic acid methyl ester and the diazonium salts of the appropriate amines; the ester function was then hydrolysed in basic conditions²¹. The general procedures, the synthetic pathways (Supplementary Schemes 1 and 2), the details concerning the specific synthetic steps and the analytical data are provided in the Supplementary Material.

Mbtl enzymatic assays

Recombinant *M. tuberculosis* Mbtl was produced and purified as previously reported¹⁴. Enzyme activity was determined measuring the production of salicylic acid by a fluorimetric assay slightly modified from Vasan et al.¹² Briefly, assays were performed at 37 °C in a final volume of 400 μL of 50 mM Hepes pH 7.5, 5 mM MgCl₂, using 1–2 μM Mbtl and the reactions were started by the addition of chorismic acid and monitored using a Perkin-Elmer LS3 fluorimeter (Ex. λ = 305 nm, Em. λ = 420 nm). Inhibition assays were performed in the presence of the compound at 100 μM (stock solution 20 mM in DMSO), at 50 μM chorismic acid. For significantly active compounds, IC₅₀ and K_i values were determined. To verify that the compounds were not PAINs, their ability to inhibit Mbtl activity was tested in the presence of 0.1 mg/mL of bovine serum albumin (BSA) or in the presence of 0.01% (v/v) Triton X-100 to confirm that they did not act as aggregate, and in the presence of 100 mM of 1,4-dithio-DL-threitol (DTT) to exclude an enzyme inhibition due to reaction with cysteines²².

Minimal inhibitory concentration determinations and siderophore production assay

The MIC⁹⁹ values of active compounds against *M. bovis* BCG were determined in low-iron Chelated Sauton's medium²³, using the resazurin reduction assay (REMA)²⁴. Siderophore activity in the culture was tested in *M. bovis* BCG using the Universal CAS liquid assay. To this purpose, *M. bovis* was grown in 7H9 medium, subcultured in chelated Sauton's medium and then diluted to an




Figure 1. Biological characterisation of **1h**. The global reciprocal plot of data from MbtI steady-state kinetics analysis towards chorismic acid, in the presence of different concentrations of **1h** (A), highlights the competitive behaviour of the inhibitor. IC_{50} plots of **1h** in the presence of BSA (green squares), Triton X-100 (red triangles) and DTT (yellow diamonds) (B) confirm that the compound is not a PAIN. The Universal CAS assay performed on culture media of *M. bovis* BCG cells grown in the presence of **1h** (C), together with the determination of the mycobactins in the above-mentioned cells (D), confirm that the antimycobacterial activity is related to iron uptake inhibition. All data are mean \pm SD of three replicates.

OD_{600} of 0.01 in chelated Sauton's containing different concentrations of the test compound. After 15 days of incubation at 37 °C, cells were harvested, supernatants were used to perform CAS assay and cell pellets were used for the determination of mycobactins. For CAS assay, an aliquot of 100 μ L of supernatant was mixed with 100 μ L of CAS assay liquid solution in a 96-well plate, incubated for 10 min at room temperature, and the absorbance was measured at 630 nm. For mycobactin determination, cell pellets were extracted in ethanol overnight, then 0.1 M $FeCl_3$ in ethanol was added until no color change was observed. The mixture was incubated at room temperature for 1 h, then mycobactins were extracted in chloroform, washed with water, evaporated and the residue was dissolved in methanol. The concentration of mycobactins was determined measuring the absorbance at 450 nm (1% solution of mycobactins gives an absorbance of 42.8).

Cell viability assay

MRC5 human fibroblast lung cells were maintained at 37 °C in a humidified atmosphere containing 5% CO_2 , according to the

supplier's indications. Cells (10^4) were plated in 96-well culture plates. The day after seeding, vehicle or compounds were added at different concentrations to the medium. Compounds were added to the cell culture at a concentration ranging from 200 to 0.01 μ M. Cell viability was measured after 96 h according to the supplier's instructions (Promega, cat. n° G7571) with a Tecan M1000 PRO instrument. IC_{50} values were calculated from logistic dose-response curves.

Docking studies

All the compounds were docked into the minimised average structure of MbtI complexed with the lead compound **1**¹⁴. The software Gold with the four fitness functions implemented (i.e. GoldScore, ChemScore, Astex Statistical Potential, and ChemPLP) and plants were employed in this study as previously reported^{14,25}, since they have been already used showing good results in the previous virtual screening study on MbtI inhibitors performed in our laboratory¹⁵. The docking site was defined as the region comprising all residues that stayed within 10 Å from




Figure 2. Minimised average structure of **1h** within MbtI binding site.

the reference compound **1**. By applying the five docking methods, five different binding dispositions (best-scored docking pose) resulted from the docking of each ligand into the protein binding site. The RMSD of these docking poses against the remaining four was evaluated by using the *rms_analysis* software of the Gold suite. On this basis, for each ligand docked into the protein binding site, a 5×5 matrix was generated reporting the RMSD results. By using an in-house programme, these results were clustered, so that among the five results, all of the similar docking poses were grouped together²⁶. We selected an RMSD clustering threshold of 2.0 Å; therefore, the so-obtained clusters contained the group of poses that were less than 2.0 Å away from all others poses belonging to the same cluster. For each compound, the binding mode belonging to the most populated cluster identified by the consensus docking evaluation was taken into consideration and subjected to MD simulations.

MD simulations

All simulations were performed using AMBER 16²⁷. General amber force field (GAFF) parameters were assigned to the ligands, whereas partial charges were determined using the AM1-BCC method as implemented in the Antechamber suite of AMBER16. MD simulations were carried out employing the ff14SB force field at 300 K. Magnesium ion was inserted considering its disposition and interaction into the 2FN1 PDB code. Ligand-protein complexes were placed in a rectangular parallelepiped water-box and solvated with a 20 Å water cap by using the TIP3P explicit solvent model. Sodium ions were added as counterions in order to neutralise the system. Before MD simulations, two steps of minimisation were performed; in the first stage, a position constraint of 500 kcal/(mol·Å²) was applied to keep the protein fixed thus minimising only water molecules. In the second stage, the whole system was energy minimised through 5000 steps of steepest descent followed by conjugate gradient (CG), until a convergence of 0.05 kcal/(mol·Å²) and imposing a harmonic potential of 10 kcal/(mol·Å²) to the protein α carbon. Particle mesh Ewald (PME) electrostatics and periodic boundary conditions were used

in the simulations. The time step of the simulations was 2 fs with a cutoff of 10 Å for the non-bonded interactions, while the SHAKE algorithm was applied to keep all bonds involving hydrogen atoms fixed. Constant-volume periodic boundary MD simulation was carried out for the first 0.5 ns, during which the temperature of the system was raised from 0 to 300 K. Then 19.5 ns of constant-pressure periodic boundary MD was performed at 300 K, using the Langevin thermostat in order to maintain constant the temperature of the system. A harmonic force constraint of 10 kcal/(mol·Å²) was applied to the protein α carbons during the first 3.5 ns, whereas in the last 16.5 ns no restraints were applied to the system. All the obtained MD trajectories were analyzed using the Cpptraj programme implemented in AMBER 16.

Result and discussion

In order to further develop our library of furan-based candidates, we examined the substitution pattern at the *para* and *ortho* positions of the phenyl ring. Herein, we disclose additional SAR data; firstly, we synthesised a phenyl di-substituted analog of **1**, characterised by the presence of the trifluoromethyl group (**1a**), because we knew that the more druggable *p*-CF₃ in place of the *p*-NO₂ group was still able to inhibit MbtI¹⁴. Compound **1a** displayed encouraging inhibiting properties (residual enzyme activity at 100 μM, as % RA, of 6.1 ± 2.5 , IC₅₀ = 28.5 ± 2.6 μM). Therefore, we took into account this compound as a new hit and we focussed on the effects of a variety of electron donating/withdrawing or hydrophilic groups in the *ortho* position of the phenyl ring, keeping the CF₃ group in *para* position (**1b-i**). Then, the effects of the previously analysed substituents in *ortho* position were evaluated in the second series of derivatives **1j-p**, bearing the original *p*-NO₂ group (Table 1).

The activity of all compounds (**1a-p**) was tested against the recombinant MbtI, prepared and assayed as previously reported¹⁴. The substitution of the chlorine atom with the fluorine in **1b** did not affect the activity, while the introduction of the bromine atom in **1c** diminished the inhibitory effect of the compound (% RA 38.0 ± 3.7), due to the low capability of bromine to act as

hydrogen bond acceptor together with its higher atomic radius determining a negative steric constraint. The presence of the electron donating groups in **1d**, **1e**, and **1f** did not lead to an improvement of the biological effects. When an electron withdrawing moiety was introduced in the *ortho* position, as in **1g**, we detected an increased activity. This outcome was confirmed by the introduction of an *o*-CF₃ moiety that led to the disclosure of **1h**, having an IC₅₀ value comparable to that of the most active inhibitor (**1**), previously identified. Derivative **1i** was then prepared and tested to assess the importance of having the electron withdrawing moiety in *ortho* position of the phenyl ring; interestingly, moving the CF₃ to the *meta* position significantly decreased the inhibitory activity of the compound. A parallel trend of biological results was obtained for the *p*-NO₂ derivatives **1j–p**. These compounds were prepared and tested to compare the impact of the CF₃ and NO₂ groups on the activity and to better understand their role in the interaction with the target. The outcomes reflected the similar biological behaviour observed for this series (**1j–p**) with respect to the previous one (**1a–i**), confirming the ability of CF₃ to act as a bioisostere of the nitro moiety, according to the bioisosterism between fluorine and carbonyl functionality²⁸. Of note, the presence of two CF₃ substituents in **1h** synergically contributed to enhance the activity, as shown by the comparison of the IC₅₀ value of **1h** and the respective derivative **1p** belonging to the *para*-nitro series (13.1 vs. 41.8 μM).

For the most active compound, **1h**, an accurate biological analysis was thus performed (Figure 1). Kinetic analysis allowed the determination of the *K_i* value 8.8 ± 0.7 μM, allowing the classification of this compound as competitive inhibitor of Mbtl. Then, additional tests were performed to verify that **1h** was not a PAIN compound. The addition of BSA and Triton X-100 did not influence its IC₅₀, proving that the compound did not form aggregates with the target. Similarly, the addition of DTT did not impact on **1h** activity, showing that the ligand did not interact with the cysteine residues of the protein. To evaluate the antimycobacterial activity of **1h** we used the nonpathogenic *M. bovis* BCG, whose siderophores closely resemble *Mtb* mycobactins^{29,30}. The minimal inhibitory concentration (MIC⁹⁹) value, determined in iron-limiting conditions in chelated Sauton's medium, was similar to that of hit **1** (250 μM versus 500 μM). Moreover, to assess if the antitubercular activity was indeed related to iron uptake inhibition, the effects of the compound on siderophore production were evaluated by means of the Universal CAS liquid assay³⁰. Firstly, the level of siderophore activity in the medium was measured and the colorimetric assay revealed that the removal of iron was inversely related to the concentration of the compound. Similarly, the quantification of mycobactins isolated from the cell pellet evidenced that the concentration of mycobactins decreased at higher **1h** concentrations. All these outcomes suggested that the inhibitory effect towards *Mtb* growth was due to mycobactin biosynthesis inhibition. Finally, compounds **1**, **1h** and **1p** were selected for evaluating their antiproliferative activity against human MRC-5 fibroblasts. The biological results showed that the three compounds did not affect the growth of these normal cells (MRC-5, IC₅₀ > 100 μM), thus indicating the potentially low level of toxicity of this class of compounds.

With the aim of elucidating the binding mode of this class of derivatives, molecular modelling studies were performed on the most active compound of the series. Compound **1h** was subjected to a consensus docking protocol and the result was refined through 20 ns of MD simulation with explicit water molecules (see Supplementary Material for details). Figure 2 shows the minimised average structure of **1h** bound to the catalytic site of Mbtl. The

two aromatic rings of the ligand lay on the hydrophobic wall constituted by I207, P251, T361, and L404, thus forming lipophilic interactions with these residues. On the other side of the binding site, the ligand core moiety shows multiple interactions with K438: a hydrogen bond formed by the furan oxygen and a cation-π interaction established through the phenyl ring, which also forms additional hydrophobic contacts with the side chain of the residue. The carboxylic group of **1h** coordinates the Mg²⁺ ion and also forms H-bonds with the backbone nitrogen of G270 and the side chain of K205 that contribute to anchor the ligand to the Mbtl binding site. According to the experimental results, the *p*-CF₃ group of the ligand replaces the *p*-NO₂ group of the parent compound **1** by forming two H-bonds with the backbone nitrogen of R405 and G419, while the *o*-CF₃ substituent of **1h** shows an additional hydrogen bond with the side chain of H334. The same consensus docking and MD protocols were then applied on compounds **1a** and **1q** to gain a better interpretation of the obtained SAR. In agreement with the experimental data, the binding mode predicted for **1a** confirmed the importance of the *o*-CF₃ substituent of **1h**. In fact, the *o*-chlorine atom of **1a** does not show any hydrogen bond with H334. Moreover, although the ligand perfectly chelates the Mg²⁺ ion, the presence of the chlorine atom determines a small shift in the binding orientation that hampers the formation of H-bonds with G270 and K205 predicted for **1h** (Figure S1). Nevertheless, the presence of an *o*-CF₃ moiety was found to be detrimental when associated with the *p*-NO₂ group originally present in **1**, as observed for compound **1p**. Interestingly, MD simulations suggested that **1p** is not able to form the H-bond and cation-π interactions with K438 (Figure S2). In order to establish the H-bond network among its *p*-NO₂ group, the backbone nitrogen of R405 and the side chain of Y385, **1p** moves toward these residues and slightly rotates toward K438, which thus moves away from the ligand to avoid steric clashes. Due to its orientation within Mbtl binding site, **1p** cannot even interact with H334 through the *o*-CF₃ as predicted for **1h**.

To conclude, starting from the analysis of the hypothetical binding mode of our previous furan-based hit **1**, we successfully performed the bioisosteric replacement of the nitro group. Our preliminary hit optimisation study led to the disclosure of a new compound (**1h**) exhibiting a strong activity against Mbtl, comparable to the most potent competitive inhibitor reported so far¹⁴. Our best candidate **1h**, characterised by the presence of two CF₃ substituents in the *ortho* and *para* positions of its phenyl ring, displayed an IC₅₀ value of 13.1 ± 2.0 μM (*K_i* = 8.8 ± 0.7 μM) and the antimycobacterial activity showed by this compound (MIC⁹⁹ = 250 μM) is conceivably related to mycobactin biosynthesis inhibition. Moreover, preliminary assays against noncancerous human fibroblast lung cells did not reveal cytotoxicity issues. These results support the hypothesis that 5-phenylfuran-2-carboxylic derivatives are a promising class of Mbtl inhibitors and allowed us to gather new information for a further optimisation of this class of compounds.

Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

This work was funded by University of Milan (Linea B), and the Italian Ministry of Education, University and Research (MIUR): Dipartimenti di Eccellenza Programme (2018–2022) - Dept. of Biology and Biotechnology "L. Spallanzani", University of Pavia.

ORCID

Laurent R. Chiarelli  <http://orcid.org/0000-0003-0348-9764>
 Matteo Mori  <http://orcid.org/0000-0002-7491-1494>
 Giangiacomo Beretta  <http://orcid.org/0000-0003-0987-0857>
 Arianna Gelain  <http://orcid.org/0000-0001-9104-732X>
 Elena Pini  <http://orcid.org/0000-0003-0554-566X>
 Josè Camilla Sammartino  <http://orcid.org/0000-0003-3707-3118>
 Giovanni Stelitano  <http://orcid.org/0000-0002-5219-4770>
 Daniela Barlocco  <http://orcid.org/0000-0002-8593-1853>
 Luca Costantino  <http://orcid.org/0000-0001-5334-8084>
 Giulio Poli  <http://orcid.org/0000-0002-8061-5632>
 Isabella Caligiuri  <http://orcid.org/0000-0002-4355-5597>
 Flavio Rizzolio  <http://orcid.org/0000-0002-3400-4363>
 Marco Bellinzoni  <http://orcid.org/0000-0002-8887-6917>
 Tiziano Tuccinardi  <http://orcid.org/0000-0002-6205-4069>
 Stefania Villa  <http://orcid.org/0000-0001-6616-1163>
 Fiorella Meneghetti  <http://orcid.org/0000-0002-6511-7360>

References

1. Glaziou P, Floyd K, Raviglione MC. Global epidemiology of tuberculosis. *Semin Respir Crit Care Med* 2018;39:271–85.
2. Zhang Y, Yew W. Mechanisms of drug resistance in *Mycobacterium tuberculosis*. *Int J Tuberc Lung Dis* 2009;13:1320–30.
3. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. *Lancet* 2010;375:1830–43.
4. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. *Eur Respir J* 2013;42:156–68.
5. Koul A, Arnoult E, Lounis N, et al. The challenge of new drug discovery for tuberculosis. *Nature* 2011;469:483–90.
6. Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. *Nat Rev Drug Discov* 2013;12:388–404.
7. Fanzani L, Porta F, Meneghetti F, et al. *Mycobacterium tuberculosis* low molecular weight phosphatases (MPtpA and MPtpB): from biological insight to inhibitors. *Curr Med Chem* 2015;22:3110–32.
8. Meneghetti F, Villa S, Gelain A, et al. Iron acquisition pathways as targets for antitubercular drugs. *Curr Med Chem* 2016;23:4009–26.
9. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. *Eur Respir J* 2017;49:1700387.
10. D'Ambrosio L, Centis R, Tiberi S, et al. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. *J Thorac Dis* 2017;9:2093–101.
11. De Voss JJ, Rutter K, Schroeder BG, et al. The salicylate-derived mycobactin siderophores of *Mycobacterium tuberculosis* are essential for growth in macrophages. *Proc Natl Acad Sci USA* 2000;97:1252–7.
12. Vasan M, Neres J, Williams J, et al. Inhibitors of the salicylate synthase (MbtI) from *Mycobacterium tuberculosis* discovered by high-throughput screening. *ChemMedChem* 2010;5:2079–87.
13. Manos-Turvey A, Cergol KM, Salam NK, et al. Synthesis and evaluation of *M. tuberculosis* salicylate synthase (MbtI) inhibitors designed to probe plasticity in the active site. *Org Biomol Chem* 2012;10:9223.
14. Chiarelli LR, Mori M, Barlocco D, et al. Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents. *Eur J Med Chem* 2018;155:754–63.
15. Pini E, Poli G, Tuccinardi T, et al. New chromane-based derivatives as inhibitors of *Mycobacterium tuberculosis* salicylate synthase (MbtI): preliminary biological evaluation and molecular modeling studies. *Molecules* 2018;23:1506.
16. Harrison AJ, Yu M, Gardenborg T, et al. The structure of MbtI from *Mycobacterium tuberculosis*, the first enzyme in the biosynthesis of the *Siderophore mycobactin*, reveals it to be a salicylate synthase. *J Bacteriol* 2006;188:6081–91.
17. Nepali K, Lee H-Y, Liou J-P. Nitro-group-containing drugs. *J Med Chem* 2018. [Epub ahead of print]. doi:10.1021/acs.jmedchem.8b00147
18. Porta F, Gelain A, Barlocco D, et al. A field-based disparity analysis of new 1,2,5-oxadiazole derivatives endowed with antiproliferative activity. *Chem Biol Drug Des* 2017;90:820–39.
19. Masciocchi D, Gelain A, Porta F, et al. Synthesis, structure–activity relationships and stereochemical investigations of new tricyclic pyridazinone derivatives as potential STAT3 inhibitors. *Medchemcomm* 2013;4:1181.
20. Gorak YI, Obushak ND, Matiichuk VS, Lytvyn RZ. Synthesis of heterocycles from arylation products of unsaturated compounds: XVIII. 5-Arylfuran-2-carboxylic acids and their application in the synthesis of 1,2,4-thiadiazole, 1,3,4-oxadiazole, and [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives. *Russ J Org Chem* 2009;45:541–50.
21. Cattò C, Grazioso G, Dell'Orto S, et al. The response of *Escherichia coli* biofilm to salicylic acid. *Biofouling* 2017;33:235–51.
22. Dahlin JL, Nissink JWM, Strasser JM, et al. PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. *J Med Chem* 2015;58:2091–113.
23. Siegrist MS, Unnikrishnan M, McConnell MJ, et al. Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. *Proc Natl Acad Sci USA* 2009;106:18792–7.
24. Palomino J-C, Martin A, Camacho M, et al. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2002;46:2720–2.
25. Tuccinardi T, Poli G, Dell'Agnello M, et al. Receptor-based virtual screening evaluation for the identification of estrogen receptor β ligands. *J Enzyme Inhib Med Chem* 2015;30:662–70.
26. Poli G, Martinelli A, Tuccinardi T. Reliability analysis and optimization of the consensus docking approach for the development of virtual screening studies. *J Enzyme Inhib Med Chem* 2016;31:167–73.
27. Case DA, Berryman JT, Betz RM, Cerutti DS, Cheatham III TE, Darden TA, Duke RE, Giese TJ, Gohlke H, Goetz AW, et al. 2015. AMBER, Version 14. San Francisco, CA: University of California.
28. Meanwell NA. Fluorine and fluorinated motifs in the design and application of bioisosteres for drug design. *J Med Chem* 2018;61:5822–80.
29. Brosch R, Philipp WJ, Stavropoulos E, et al. Genomic analysis reveals variation between *Mycobacterium tuberculosis* H37Rv and the attenuated *M. tuberculosis* H37Ra strain. *Infect Immun* 1999;67:5768–74.
30. Schwyn B, Neilands JB. Universal chemical assay for the detection and determination of siderophores. *Anal Biochem* 1987;160:47–56.